SCHEMBL3387704

SCHEMBL3387704

CCCN(C1CCc2ccc([N+](=O)[O-])cc2C1)C(C1CCNCC1)S(C)(=O)=O

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 9/20 0.39
DRD3 P35462 9/20 0.38
DRD4 P21917 5/20 0.38
ADRA2A P08913 4/20 0.38
PNMT P11086 4/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
ADRA2B P18089 2/20 0.37
ADRA2C P18825 2/20 0.37
HTR1A P08908 1/20 0.37
ADRB2 P07550 1/20 0.37
CYP2D6 P10635 1/20 0.37
CASP1 P29466 1/20 0.37
LMNA P02545 2/20 0.36
MAPT P10636 1/20 0.36
MCHR1 Q99705 1/20 0.36
HTR1D P28221 1/20 0.35
HTR1B P28222 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3390091 0.85 DRD3 (0.42) DRD2DRD3DRD4MEN1KMT2A
SCHEMBL6337081 0.85 DRD3 (0.40) DRD2DRD3DRD4MEN1KMT2A
SCHEMBL6335385 0.84 DRD2 (0.57) DRD2DRD3DRD4MEN1KMT2A
SCHEMBL6345233 0.84 DRD2 (0.57) DRD2DRD3DRD4MEN1KMT2A
SCHEMBL6336496 0.83 DRD3 (0.46) DRD2DRD3DRD4MEN1KMT2A
SCHEMBL6345257 0.83 DRD3 (0.41) DRD2DRD3DRD4MEN1KMT2A
SCHEMBL6344096 0.80 DRD3 (0.57) DRD2DRD3DRD4
SCHEMBL6634307 0.80 DRD3 (0.37) DRD2DRD3DRD4MEN1KMT2A
SCHEMBL6619115 0.80 DRD2 (0.48) DRD2DRD3DRD4HTR1D
SCHEMBL6334415 0.80 ALDH1A1 (0.44) DRD2DRD3DRD4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1453805-B1 4-PIPERIDINYL ALKYLAMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2010-12-22 EP disclosed
US-6864266-B2 4-piperidinyl alkyl amine derivatives as muscarinic receptor antagonists SYNTEX (U.S.A.) LLC (US) 2005-03-08 US disclosed
EP-1453805-A1 4-PIPERIDINYL ALKYLAMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-09-08 EP disclosed
US-20040092554-A1 4-piperidinyl alkyl amine derivatives as muscarinic receptor antagonists BROTHERTON-PLEISS CHRISTINE E (US) 2004-05-13 US disclosed
US-6627644-B2 Muscarinic receptor antagonists and parasympathetic nervous system. The physiological actions of Acetylcholine are mediated by activation of either nicotinic or muscarinic receptors SYNTEX (U.S.A.) LLC 2003-09-30 US disclosed
US-20030162780-A1 4-PIPERIDINYL ALKYL AMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS SYNTEX (U.S.A.) LLC, NAME CHANGED TO ROCHE PALO ALTO LLC 2003-08-28 US disclosed
WO-2003048124-A1 4-PIPERIDINYL ALKYLAMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162780-A1 4-PIPERIDINYL ALKYL AMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS CHRM1, CHRM3, CHRM2 DRD2 50/4885DRD3 56/4885DRD4 149/4885
US-20040092554-A1 4-piperidinyl alkyl amine derivatives as muscarinic receptor antagonists CHRM1, CHRM3, CHRM2 DRD2 50/4885DRD3 56/4885DRD4 149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.